WHO warns of immunisation strategy gaps amid measles outbreaks
The World Health Organisation (WHO) has reported a sharp drop in deaths from measles in recent decades yet warned that…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
Podcast: What key trends are people talking about in pharma?
As the last leaves of Autumn fall, the healthcare conference scene ramps up its activity before the end of the…
-
Valneva trims R&D footprint by shutting French facility
Not long after cutting its sales forecast for 2025, Valneva has decided to decrease its operational footprint in France by…
-
Dupixent gains chronic spontaneous urticaria indication in Europe
Regeneron and Sanofi’s Dupixent (dupilumab) has gained approval to treat chronic spontaneous urticaria (CSU) in Europe, adding yet another indication to…
-
Questions on how new IRA drug prices will affect MFN agreements
As the US Centers for Medicare and Medicaid Services (CMS) has released the new prices for 15 drugs that have been…
-
UK-developed leukaemia cell therapy to be offered on NHS
A UK-developed cell therapy to treat a form of leukaemia has been greenlit for use on England’s National Health Service…
-
Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club
Eli Lilly’s market capitalisation hit the $1tn mark in the past week, becoming the first healthcare company in the world…
-
Galapagos CEO tightens strategic focus in pursuit of key assets
For many observers, Galapagos is in an enviable position. The biotech has a balance sheet of €3bn to call upon…
-
“Reckless and harmful”: experts weigh in on CDC’s autism-vaccine link stance
The Centers for Disease Control and Prevention (CDC) has updated its website to state that there could be a link…
-
Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership
Merck KGaA has signed a drug discovery partnership with Valo Health, becoming the latest big pharma to enlist the services…